Ranibizumab Therapy for Neovascular AMD in eyes with good vision (>6/12): visual outcomes and cost-effectiveness based on real world outcomes of 92,976 treatment episodes

Adnan Tufail(Moorfields Eye Hospital), Thomas Butt(University College London), Cecilia S. Lee(University of Washington), Dawn A. Sim(Moorfields Eye Hospital NHS Foundation Trust), Robert L. Johnston(Cheltenham General Hospital), Catherine Egan(Maine Farmland Trust), Aaron Lee(Imperial College London)
Investigative Ophthalmology & Visual Science
June 11, 2015
Cited by 0

Related Papers

Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension
|Nature Medicine|2020|1.2k
Deep Learning Is Effective for Classifying Normal versus Age-Related Macular Degeneration OCT Images
|Ophthalmology Retina|2017|669
Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension
|Nature Medicine|2020|665
Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI
|Nature Medicine|2022|636
A Prospective Randomized Trial of Intravitreal Bevacizumab or Laser Therapy in the Management of Diabetic Macular Edema (BOLT Study)
|Ophthalmology|2010|510